Small molecule inhibitors of cancer stem cells and mesenchymal cancer types

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 12263165
APP PUB NO 20230346781A1
SERIAL NO

18350550

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present disclosure provides compounds, their pharmaceutical compositions, and methods of their use for treating mesenchymally-derived or mesenchymally-transformed cancers, such as breast cancers and sarcomas, and for treating diseases or disorders that are characterized by the expression of vimentin.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • THE SCRIPPS RESEARCH INSTITUTE; 501 BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bollong, Michael J San Diego, US 5 1
Lairson, Luke L San Diego, US 8 1
Mani, Sendurai A Houston, US 7 6
Schultz, Peter G La Jolla, US 236 4625

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Oct 1, 2028
7.5 Year Payment $3600.00 $1800.00 $900.00 Oct 1, 2032
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 1, 2036
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00